Press

Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study

Aug 15 • 3 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has received approval from the U.K. Medicines and Healthcare products Regulatory Authority and the Regional Ethics Committee to initiate a drug interaction clinical trial in the U.K. The study will assess…

Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments

Aug 15 • 2 min read

Awakn Life Sciences Corp. (NEO: AWKN | OTCQB: AWKNF | FSE: 954), a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction, announced today that Awakn Clinics London has received Care Quality Commission’s (CQC) formal approval to begin treatments for addiction and mental health. The flagship London clinic is Awakn’s third clinic, adding…

Core One Labs’ Subsidiaries Successfully Produce Psilocin Precursor for Production to Psilocybin

Aug 15 • 3 min read

Core One Labs Inc. (CSE: COOL | OTCQB: CLABF | Frankfurt: LD6 | WKN:A3CSSU), is pleased to announce that scientists at its wholly-owned subsidiary Awakened Biosciences Inc. have successfully produced a precursor that can be efficiently converted into psilocin, the psychoactive ingredient of psilocybin, with further conversion into commercially viable psilocybin by Core One’s wholly owned…

MindMed Strengthens Board with Appointment of Two New Independent Directors

Aug 12 • 6 min read

Mind Medicine Inc. (NASDAQ: MNMD | NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors. “We are pleased to welcome both Dr. Bruhn and Dr. Crystal to our Board. Their collective…

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Aug 12 • 5 min read

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the three and six months ended June 30, 2022. The Company will host a conference call today, Thursday, August 11, at 4:30 PM Eastern Time/1:30 PM Pacific Time. Recent…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435